A Randomized, Placebo-Controlled Trial of Acupuncture in Patients With Chronic Obstructive Pulmonary Disease (COPD)

This Japanese study represents an important milestone in research on acupuncture for respiratory diseases, being the first randomized controlled trial to definitively demonstrate the efficacy of acupuncture in treating exertional dyspnea in patients with chronic obstructive pulmonary disease (COPD). COPD is a debilitating condition characterized by irreversible airflow limitation, projected to be the third leading cause of death worldwide by 2030. Dyspnea, or shortness of breath, is the most fundamental and disabling symptom of COPD, significantly affecting patients' quality of life. Effective dyspnea management represents one of the main therapeutic goals in COPD treatment.

The researchers conducted a prospective, randomized, placebo-controlled, single-blind study between July 2006 and March 2009 in the Kansai region of Japan. Sixty-eight patients diagnosed with COPD GOLD stages II, III, or IV, who were receiving standard medication, were randomized to receive verum acupuncture or placebo treatment. The protocol used a specially designed Park sham device to ensure adequate blinding, in which the placebo needles appeared to penetrate the skin but actually retracted telescopically. Treatment was applied at 11 standardized acupuncture points selected according to traditional Chinese medicine theory and prior clinical experience: LU-1 (Zhongfu) and LU-9 (Taiyuan) on the lung meridian; LI-18 (Futu) on the large intestine meridian; CV-4 (Guanyuan) and CV-12 (Zhongwan) on the conception vessel; ST-36 (Zusanli) on the stomach meridian; KI-3 (Taixi) on the kidney meridian; GB-12 (Wangu) on the gallbladder meridian; and BL-13 (Feishu), BL-20 (Pishu), and BL-23 (Shenshu) on the bladder meridian.

Sessions lasted 50 minutes, once a week for 12 weeks. The primary outcome was the score on the 10-point modified Borg scale assessed immediately after the 6-minute walk test. The results were impressive and clinically significant. After 12 weeks, the Borg scale score improved from 5.5 to 1.9 in the verum acupuncture group (a 3.6-point reduction), while it remained practically unchanged in the placebo group (4.2 to 4.6 points).

The mean between-group difference was -3.58 points (95% CI: -4.27 to -2.90), exceeding the clinically important difference threshold of 2 points established in the literature. The distance walked in the 6-minute test also improved significantly in the verum acupuncture group (+63.5 meters) compared to the placebo group (-19.4 meters), with a between-group difference of 78.68 meters (95% CI: 54.16 to 103.21). Additionally, the lowest oxygen saturation during the test improved by 3.5% in the verum acupuncture group versus a drop of 1.6% in the placebo group. Secondary outcomes showed consistent improvements in the verum acupuncture group.

Quality of life measured by the St. George's Respiratory Questionnaire improved significantly, with a 16-point reduction in the total score, well above the clinically important difference threshold of 4 points. Pulmonary function parameters, including forced vital capacity, forced expiratory volume, and diffusing capacity for carbon monoxide, also improved significantly. Notably, respiratory muscle strength increased substantially, with maximal expiratory pressure improving by 34.4 cmH2O and maximal inspiratory pressure by 13.8 cmH2O in the verum acupuncture group.

The study also revealed improvements in nutritional status, with increases in body mass index and pre-albumin levels, suggesting that acupuncture may help reverse the malnutrition common in COPD patients. Chest wall mobility increased significantly (3.1 cm), indicating improvement in respiratory mechanics. The mechanisms proposed by the authors include relaxation of hyperactivated respiratory muscles, improvement of chest wall mobility, and possible correction of autonomic tone. Treatment safety was excellent, with only minor adverse reactions reported, including fatigue, mild subcutaneous bleeding, dizziness, and pain at the needle site, all resolving quickly.

Study limitations include the relatively short follow-up period without long-term follow-up assessment, the fact that most patients were already on standard COPD medication, and the impossibility of fully blinding acupuncturists, although this is a common challenge in acupuncture studies. This study provides robust evidence that acupuncture is a useful and safe adjunctive therapy to reduce exertional dyspnea in COPD patients, offering a valuable nonpharmacological therapeutic option for a condition with limited treatment options.